DIRS.INFO The most relevant business & tech news

☆ A controversial study says intermittent fasting may shorten your lifespan. It shows how little we really know about the long-term effects.
▼ + stars: | 2024-03-18 | by ( ) www.businessinsider.com time to read: +7 min

A new study links intermittent fasting to a higher risk of early death instead of longevity. While there's not yet enough evidence to say intermittent fasting is risky, the findings suggest we may have a lot more to learn about whether it's good for our health in the long run. However, some rigorous studies on intermittent fasting have found mixed results: some suggest it's no better for you than other diets, and isn't worth the side effects like hunger. people who follow the 16:8 diet — would have a lower risk of dying during the study, and better heart health. Advertisement"Overall, this study suggests that time-restricted eating may have short-term benefits but long-term adverse effects," Gardner said in a press release.

Persons: —, there's, Victor Wenze Zhong, Krista Varady, Varady, David Spiegelhalter, Christopher D, Gardner, Zhong Organizations: Service, Shanghai Jiao Tong University School of Medicine, American Heart Association, University of Illinois Chicago, University of Cambridge Locations: Shanghai, China, Chicago, Stanford

☆ Eli Lilly vs. Novo Nordisk: The pros deliver their verdict on the viral weight-loss stocks
▼ + stars: | 2023-12-06 | by ( Amala Balakrishner | ) www.cnbc.com time to read: +4 min

It has been quite a year for both Eli Lilly and Novo Nordisk given the boom in weight-loss drugs. Shares in Eli Lilly are up around 60% year-to-date, while its Danish counterpart Novo Nordisk has seen a gain of around 50%. At present, both Eli Lilly and Novo Nordisk offer weight loss treatments. Novo Nordisk Novo Nordisk's Wegovy recently made headlines for reducing the risk of heart attacks and strokes by 20% in adults with heart disease and obesity. Aside from Eli Lilly and Novo Nordisk, Pfizer , Johnson & Johnson and AstraZeneca are also developing weight-loss drugs.

Persons: Eli Lilly, Stocks, Rahul Ghosh, Rowe Price, TRP's Ghosh, Eli Lilly's, Ghosh, FactSet, Lilly, Novo Nordisk Novo Nordisk's Wegovy, Elizabeth Field, Squawk, What's, it's, Michael Bloom Organizations: Novo Nordisk, Nordisk, CNBC Pro, U.S . Food, Administration, pharma, Novo Nordisk Novo Nordisk's, Heart Association Scientific, Citi, Pfizer, Johnson, AstraZeneca, Barclays Locations: Danish, U.S, Novo

☆ Novo Nordisk's weight loss drug Wegovy slashes risk of serious heart events
▼ + stars: | 2023-11-11 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +2 min

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. Novo Nordisk's Wegovy cut the risk of serious cardiovascular complications in people with obesity and heart disease in a closely watched trial, demonstrating a particularly large effect on heart attacks, a promising new frontier for the drug. The roughly 17,500-person Select study tested Wegovy in people with obesity and heart disease but who did not have diabetes. The new data could also help the Danish pharmaceutical company maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was approved in the U.S. earlier this week. Zepbound has been shown to help people lose more weight, but it hasn't yet demonstrated an effect on cardiovascular outcomes.

Persons: Robert Kushner, Eli Lilly, Zepbound, Howard Weintraub Organizations: Wegovy, American Heart Association Scientific Sessions, New England, of Medicine, Novo Nordisk, Northwestern University Feinberg School of Medicine, Center for, NYU Langone Locations: Danish, U.S

☆ Marijuana use raises risk of heart attack, heart failure and stroke, studies say
▼ + stars: | 2023-11-06 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +6 min

CNN —Older adults who don’t smoke tobacco but do use marijuana were at higher risk of both heart attack and stroke when hospitalized, while people who use marijuana daily were 34% more likely to develop heart failure, according to two new non-published studies presented Monday at the American Heart Association Scientific Sessions in Philadelphia. “You need to treat this just like you would any other risk factor (for heart disease and stroke), and honestly understand the risks that you were taking,” he said. Heart failure doesn’t mean the heart has stopped working, but that the heart isn’t pumping oxygenated blood as well as it should, according to the AHA. At the end of the study, researchers found people who reported daily marijuana use had a 34% increased risk of developing heart failure, compared to those who reported never using marijuana. Also called atherosclerosis, CAD is the most common type of heart disease, according to the US Centers for Disease Control and Prevention.

Persons: ” Robert Page II, ”, Westend61, Avilash, ” Page, it’s, Yakubu Bene, Alhasan Organizations: CNN, American Heart Association Scientific Sessions, Heart, Cannabis, Cardiovascular Health, University of Colorado Skaggs School of Pharmacy, Pharmaceutical Sciences, National Institute on Drug Abuse, Nazareth Hospital, AHA, US Centers for Disease Control, Health Locations: Philadelphia, Aurora , Colorado, Baltimore

Search resuls for: "American Heart Association Scientific Sessions"

4 mentions found